Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
Interventions: DRUG: CDX-011|DRUG: Capecitabine
Sponsor: Celldex Therapeutics